BRISDELLE

Peak

paroxetine

NDAORALCAPSULE
Approved
Jun 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20

Mechanism of Action

SSRI. Paroxetine capsules are not an estrogen, and its mechanism of action for the treatment of VMS is unknown.

Clinical Trials (5)

NCT06065735Phase 1Completed

Concentration-QT Study of Paroxetine in Healthy Adults

Started Oct 2023
38 enrolled
Anxiety Disorders
NCT04311463Phase 1Completed

Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants

Started Dec 2020
38 enrolled
Anxiety Disorders
NCT03329573Phase 1Completed

Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects

Started May 2018
85 enrolled
Anxiety Disorders
NCT02932904Phase 4Completed

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Started Nov 2016
361 enrolled
Healthy Volunteers
NCT02681198Phase 1Completed

Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers

Started Jan 2016
24 enrolled
Healthy

Loss of Exclusivity

LOE Date
Apr 6, 2029
37 months away
Patent Expiry
Apr 6, 2029

Patent Records (3)

Patent #ExpiryTypeUse Code
8946251
Aug 4, 2026
SubstanceProduct
U-904
9393237
Aug 4, 2026
U-904
8658663
Apr 6, 2029
SubstanceProduct
U-904